Momenta Pharmaceuticals, Inc.'s Rough Month
Momenta Pharmaceuticals (NASDAQ: MNTA) has had a rough month or so after seeing Mylan (NASDAQ: MYL) pass it up to get the first approval of a generic version of Teva Pharmaceutical's (NYSE: TEVA) multiple sclerosis drug Copaxone 40 mg. Then its biosimilar to Orencia failed a phase 1 trial, sending shares down further.
Nevertheless, the company is pressing on highlighting other drugs in its pipeline during its third-quarter conference call and hopes that it'll be able to gain Food and Drug Administration approval for its generic version of Copaxone 40 mg, called Glatopa, later this year or early next year.
Image source: Getty Images.
Source: Fool.com
